SCHEMBL16646469

SCHEMBL16646469

CCCCOC[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)O1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 1/20 0.42
▸ PDK1 Q15118 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NR1H2 P55055 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ RECQL P46063 1/20 0.34
▸ GPR119 Q8TDV5 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16646519 1.00 ALDH1A1 (0.42) ALDH1A1HPGDPDK1SMN1; SMN2NR1H2
SCHEMBL16646329 0.91 PDK1 (0.41) ALDH1A1HPGDPDK1SMN1; SMN2PDE4A
SCHEMBL16646451 0.82 NR1H2 (0.47) ALDH1A1HPGDSMN1; SMN2NR1H2USP2
SCHEMBL24404847 0.82 NR1H2 (0.47) ALDH1A1HPGDSMN1; SMN2NR1H2USP2
SCHEMBL8140489 0.81 PDK1 (0.54) ALDH1A1PDK1SMN1; SMN2TDP1USP2
SCHEMBL17897027 0.81 PDK1 (0.54) ALDH1A1PDK1SMN1; SMN2TDP1USP2
SCHEMBL31024602 0.80 NR1H2 (0.41) ALDH1A1HPGDSMN1; SMN2NR1H2PDE4B
SCHEMBL16646516 0.80 PDK1 (0.40) ALDH1A1PDK1SMN1; SMN2NR1H2TDP1
SCHEMBL16633471 0.79 NR1H2 (0.54) ALDH1A1HPGDSMN1; SMN2NR1H2PDE4B
SCHEMBL16633062 0.79 NR1H2 (0.54) ALDH1A1HPGDSMN1; SMN2NR1H2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326161-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-11-10 — — US disclosed
US-9428495-B2 Selectively substituted quinoline compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-30 — — US disclosed
WO-2015057659-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 — — WO disclosed
US-20150105370-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326161-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS SSB, TLR7, TLR8 ALDH1A1 4592/4885HPGD 3958/4885PDK1 3299/4885
US-20150105370-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS SSB, TLR7, TLR8 ALDH1A1 4592/4885HPGD 3958/4885PDK1 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback